Epidermal growth factor receptor as a therapeutic target in lung cancer

Joan H. Schiller

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Almost two decades of research to determine how cancer cells differ from non-cancerous cells at the molecular level have been richly rewarding. Several molecular growth factors and receptors have been discovered that play a role in tumor development and are differentially expressed in tumor cells. In this regard, the structure and function of the epidermal growth factor receptor (EGFR) have been characterized. Efforts to develop effective anticancer therapy have targeted this receptor because it is critical to tumor cell proliferation, survival, and invasiveness. Overexpression of EGFR occurs in several epithelial cell tumors, including non-small cell lung cancer (NSCLC). Small-molecular- weight EGFR tyrosine kinase inhibitors and EGFR monoclonal antibodies are among the agents that have demonstrated activity against NSCLC. These compounds, which are designed to selectively target tumor cells, represent a new and novel treatment approach that is being evaluated in NSCLC clinical trials.

Original languageEnglish (US)
Pages (from-to)11-16
Number of pages6
JournalSeminars in Respiratory and Critical Care Medicine
Volume25
Issue numberSUPP. 1
StatePublished - Jun 2004

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Neoplasms
Therapeutics
Growth Factor Receptors
Protein-Tyrosine Kinases
Cell Survival
Molecular Weight
Epithelial Cells
Monoclonal Antibodies
Cell Proliferation
Clinical Trials
Research

Keywords

  • Epidermal growth factor receptor (EGFR)
  • IMC-C225
  • Non-small cell lung cancer (NSCLC)
  • Tyrosine kinase
  • ZD1839

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Critical Care

Cite this

Epidermal growth factor receptor as a therapeutic target in lung cancer. / Schiller, Joan H.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 25, No. SUPP. 1, 06.2004, p. 11-16.

Research output: Contribution to journalArticle

@article{f2fe44e810ab46dbb8cd1c6c003efb8f,
title = "Epidermal growth factor receptor as a therapeutic target in lung cancer",
abstract = "Almost two decades of research to determine how cancer cells differ from non-cancerous cells at the molecular level have been richly rewarding. Several molecular growth factors and receptors have been discovered that play a role in tumor development and are differentially expressed in tumor cells. In this regard, the structure and function of the epidermal growth factor receptor (EGFR) have been characterized. Efforts to develop effective anticancer therapy have targeted this receptor because it is critical to tumor cell proliferation, survival, and invasiveness. Overexpression of EGFR occurs in several epithelial cell tumors, including non-small cell lung cancer (NSCLC). Small-molecular- weight EGFR tyrosine kinase inhibitors and EGFR monoclonal antibodies are among the agents that have demonstrated activity against NSCLC. These compounds, which are designed to selectively target tumor cells, represent a new and novel treatment approach that is being evaluated in NSCLC clinical trials.",
keywords = "Epidermal growth factor receptor (EGFR), IMC-C225, Non-small cell lung cancer (NSCLC), Tyrosine kinase, ZD1839",
author = "Schiller, {Joan H.}",
year = "2004",
month = "6",
language = "English (US)",
volume = "25",
pages = "11--16",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "SUPP. 1",

}

TY - JOUR

T1 - Epidermal growth factor receptor as a therapeutic target in lung cancer

AU - Schiller, Joan H.

PY - 2004/6

Y1 - 2004/6

N2 - Almost two decades of research to determine how cancer cells differ from non-cancerous cells at the molecular level have been richly rewarding. Several molecular growth factors and receptors have been discovered that play a role in tumor development and are differentially expressed in tumor cells. In this regard, the structure and function of the epidermal growth factor receptor (EGFR) have been characterized. Efforts to develop effective anticancer therapy have targeted this receptor because it is critical to tumor cell proliferation, survival, and invasiveness. Overexpression of EGFR occurs in several epithelial cell tumors, including non-small cell lung cancer (NSCLC). Small-molecular- weight EGFR tyrosine kinase inhibitors and EGFR monoclonal antibodies are among the agents that have demonstrated activity against NSCLC. These compounds, which are designed to selectively target tumor cells, represent a new and novel treatment approach that is being evaluated in NSCLC clinical trials.

AB - Almost two decades of research to determine how cancer cells differ from non-cancerous cells at the molecular level have been richly rewarding. Several molecular growth factors and receptors have been discovered that play a role in tumor development and are differentially expressed in tumor cells. In this regard, the structure and function of the epidermal growth factor receptor (EGFR) have been characterized. Efforts to develop effective anticancer therapy have targeted this receptor because it is critical to tumor cell proliferation, survival, and invasiveness. Overexpression of EGFR occurs in several epithelial cell tumors, including non-small cell lung cancer (NSCLC). Small-molecular- weight EGFR tyrosine kinase inhibitors and EGFR monoclonal antibodies are among the agents that have demonstrated activity against NSCLC. These compounds, which are designed to selectively target tumor cells, represent a new and novel treatment approach that is being evaluated in NSCLC clinical trials.

KW - Epidermal growth factor receptor (EGFR)

KW - IMC-C225

KW - Non-small cell lung cancer (NSCLC)

KW - Tyrosine kinase

KW - ZD1839

UR - http://www.scopus.com/inward/record.url?scp=3042854313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042854313&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:3042854313

VL - 25

SP - 11

EP - 16

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - SUPP. 1

ER -